MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Trillium Therapeutics Company Profile (NASDAQ:TRIL)

Consensus Ratings for Trillium Therapeutics (NASDAQ:TRIL) (?)
Ratings Breakdown: 3 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $29.00 (210.83% upside)

Analysts' Ratings History for Trillium Therapeutics (NASDAQ:TRIL)
Show:
DateFirmActionRatingPrice TargetActions
6/12/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/6/2016OppenheimerReiterated RatingBuy$38.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/16/2016Leerink SwannReiterated RatingOutperform$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/26/2014 forward)
Earnings History for Trillium Therapeutics (NASDAQ:TRIL)
No earnings announcements for this company have been tracked by MarketBeat.com

Earnings Estimates for Trillium Therapeutics (NASDAQ:TRIL)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.61)($0.61)($0.61)
Q2 20161($0.71)($0.71)($0.71)
Q3 20161($0.81)($0.81)($0.81)
Q4 20161($0.91)($0.91)($0.91)
(Data provided by Zacks Investment Research)
Dividend History for Trillium Therapeutics (NASDAQ:TRIL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Trillium Therapeutics (NASDAQ:TRIL)
No insider trades for this company have been tracked by MarketBeat.com

Latest Headlines for Trillium Therapeutics (NASDAQ:TRIL)
DateHeadline
06/25/16 10:34 AMStrong Sell Calls Recommendations For Trillium Therapeutics Inc. (NASDAQ:TRIL) At 0 - Investor Newswire
06/24/16 06:55 PMRecently Issued Stock Ratings For Trillium Therapeutics Inc. (TRIL) - Fiscal Standard
06/20/16 08:18 AMCan Trillium Therapeutics Inc. (NASDAQ:TRIL) Meet Analysts Expectations? - Stocks Daily
06/20/16 08:18 AMTrillium Therapeutics Inc. (TRIL) Analyst Price Targets For The Coming Week - Fiscal Standard
06/18/16 08:22 AMStrong Buy Calls Count For Trillium Therapeutics Inc. (NASDAQ:TRIL) At 3 - Investor Newswire
06/14/16 07:34 AMDon't Miss: Trillium Therapeutics (NASDAQ:TRIL), Echo (NASDAQ:ECTE), IMS Health (NYSE:IMS), Ashford Hospitality ... - KC Register
06/08/16 05:08 PMTrillium Therapeutics, Inc. :TRIL-US: Earnings Analysis: Q1, 2016 By the Numbers : June 8, 2016 -
06/02/16 07:25 PMTrillium Therapeutics Inc's Stock Is Buy After Today's Huge Increase - HNN - Trillium Therapeutics Inc's Stock Is Buy After Today's Huge IncreaseHNNThe stock of Trillium Therapeutics Inc (TSE:TR) is a huge mover today! The stock increased 7.24% or $1.14 on June 2, hitting $16.88. About 10,429 shares traded hands or 89.17% up from the average. Trillium Therapeutics Inc (TSE:TR) has declined 18.23% ...and more »
06/01/16 07:37 PMTrillium Therapeutics Inc. (NASDAQ:TRIL)'s Company Shares Increased 1.10% After High Volatility - HNN - Trillium Therapeutics Inc. (NASDAQ:TRIL)'s Company Shares Increased 1.10% After High VolatilityHNNThe shares of Trillium Therapeutics Inc. (NASDAQ:TRIL) increased by 1.10% in the last 20 days and rose 5.54% in the past 5 trading sessions. Trillium Therapeutics Inc. (NASDAQ:TRIL) shares opened at $10.78 in the last session and had intraday high of ...
06/01/16 09:53 AMStock Review and Earnings Check on Trillium Therapeutics Inc. (NASDAQ:TRIL) - HNN - Stock Review and Earnings Check on Trillium Therapeutics Inc. (NASDAQ:TRIL)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Trillium Therapeutics Inc.and more »
05/31/16 07:18 PMTrillium Therapeutics Inc. (NASDAQ:TRIL) Stock Update & Estimates - Stock Tick Tock - Trillium Therapeutics Inc. (NASDAQ:TRIL) Stock Update & EstimatesStock Tick TockThe consensus on Wall Street is expecting Trillium Therapeutics Inc. (NASDAQ:TRIL) to post earnings of $-0.75 per share when the firm next reports it's fiscal quarterly results. According to the latest information available the report will likely be ...and more »
05/30/16 08:54 PMBroker Outlook For The Week Ahead: Trillium Therapeutics Inc. (TRIL) - Share Trading News - Broker Outlook For The Week Ahead: Trillium Therapeutics Inc. (TRIL)Share Trading NewsBroker Outlook For The Week Ahead: Trillium Therapeutics Inc. (TRIL). By Brenton Akerman / in US Broker Ratings / on Monday, 30 May 2016 06:57 PM / 0 Comments. The most recently updated broker views and price targets issued for Trillium Therapeutics ...
05/26/16 01:59 PMEarnings Review and Stock Rundown for Trillium Therapeutics Inc. (NASDAQ:TRIL) - Wall Street Hints and News - Earnings Review and Stock Rundown for Trillium Therapeutics Inc. (NASDAQ:TRIL)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Trillium Therapeutics Inc. (NASDAQ:TRIL ...
03/13/16 02:00 PMCan Trillium Therapeutics Inc. (NASDAQ:TRIL) Top Street's Expectations? - Stocks Daily - Can Trillium Therapeutics Inc. (NASDAQ:TRIL) Top Street's Expectations?Stocks DailyThe research entity Zacks Group publicized its research report on Trillium Therapeutics Inc. (NASDAQ:TRIL). It expects the company's shares to smash high of $32 in the coming year. Zacks polled 2 brokerage houses and after that fixed price target of ...and more »
03/11/16 01:57 PMTrillium Therapeutics posts loss of $2.2 million in fourth quarter - The Province - Montreal GazetteTrillium Therapeutics posts loss of $2.2 million in fourth quarterThe ProvinceTORONTO - TORONTO (AP) _ Trillium Therapeutics Inc. (TRIL) on Wednesday reported a loss of $2.2 million in its fourth quarter. The Toronto-based company said it had a loss of 28 cents per share. For the year, the company reported profit of $11 million, ...Trillium Therapeutics Inc. (NASDAQ:TRIL) Street Rating in FocusUptick Analystall 20 news articles »
03/11/16 01:57 PMTrillium Therapeutics Inc. Pipeline Review, Market Growth, Segment, Trends and Forecast 2016 – 2020 - Medgadget.com (blog) - Trillium Therapeutics Inc. Pipeline Review, Market Growth, Segment, Trends and Forecast 2016 – 2020Medgadget.com (blog)“Monosol Rx, LLC Pipeline Review, H2 2015”, provides an overview of the Monosol Rx, LLC 's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Monosol Rx, LLC, complete with comparative analysis at ...and more »
03/11/16 01:57 PMTemporary foreign worker from Mexico reaches settlement with owner of Langley blueberry farm - Trillium Therapeutics posts loss of $2.2 million in fourth quarter... TORONTO - TORONTO (AP) _ Trillium Therapeutics Inc. (TRIL) on Wednesday reported a loss of $2.2 million in its fourth quarter. Denison Mine posts loss of $24.6 million in 4th quarter ...
03/11/16 01:57 PMTrillium Therapeutics posts loss of $2.2 million in fourth quarter - TORONTO - TORONTO (AP) _ Trillium Therapeutics Inc. (TRIL) on Wednesday reported a loss of $2.2 million in its fourth quarter. The Toronto-based company said it had a loss of 28 cents per share. For the year, the company reported profit of $11 million ...
03/10/16 08:00 AMTrillium Announces a $3.4 Million Government Co-Funded Translational Research Program - [Marketwired] - Trillium Therapeutics Inc. a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has entered into a collaboration agreement with ...
03/09/16 05:28 PMTrillium reports 4Q loss -
03/09/16 04:30 PMTrillium Reports 2015 Financial and Operating Results - [Marketwired] - Trillium Therapeutics Inc. a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reports financial results for the year ended December 31, 2015 and ...
03/08/16 06:00 AMTrillium to Present at the Cowen and Company 36th Annual Health Care Conference - [Marketwired] - Trillium Therapeutics Inc. a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that Bob Uger, Ph.D., Chief Scientific Officer will present ...
03/05/16 01:25 PMStock Rating & Analysis on Trillium Therapeutics Inc. (NASDAQ:TRIL) - WallStreet.org - Stock Rating & Analysis on Trillium Therapeutics Inc. (NASDAQ:TRIL)WallStreet.orgTrillium Therapeutics Inc. (NASDAQ:TRIL) company shares are recently being watched closely by Wall Street professionals and certain individuals that give personal stock ratings (crowd). Although company fundamentals are important when predicting future ...and more »
03/03/16 01:47 PMTrillium Therapeutics Inc. (TRIL) Updated Price Targets - Share Trading News - Trillium Therapeutics Inc. (TRIL) Updated Price TargetsShare Trading NewsRecently analysts working for a variety of stock market brokerages have changed their consensus ratings and price targets on shares of Trillium Therapeutics Inc. (TRIL). The most recent broker reports which have been released note that 2 analysts have ...
03/01/16 01:50 PMWhat's Ahead for Trillium Therapeutics Inc. After Today's Huge Decline? - Business Standard Tribune - What's Ahead for Trillium Therapeutics Inc. After Today's Huge Decline?Business Standard TribuneThe stock of Trillium Therapeutics Inc. (NASDAQ:TRIL) is a huge mover today! The stock decreased 6.67% or $0.55 on February 29, hitting $7.69. Trillium Therapeutics Inc. (NASDAQ:TRIL) has declined 64.12% since July 24, 2015 and is downtrending.
02/27/16 01:12 PMTrillium Therapeutics Inc Stock Price Increases Today - RiversideGazette.com - Trillium Therapeutics Inc Stock Price Increases TodayRiversideGazette.comThe stock of Trillium Therapeutics Inc (TSE:TR) is a huge mover today! The stock increased 12.13% or $1.19 on February 26, hitting $11. About 10,520 shares traded hands or 117.49% up from the average. Trillium Therapeutics Inc (TSE:TR) has declined ...
02/18/16 01:16 PMTrillium Therapeutics Inc. (TRIL) - Trillium Therapeutics Inc., an immuno-oncology company, develops therapies for the treatment of cancer. Its primary program is SIRPaFc, an antibody-like fusion protein, which blocks the activity of CD47, a molecule that allows tumor cells to escape ...
02/03/16 06:00 AMTrillium Therapeutics Doses First Patient With TTI-621, a Novel Immune Checkpoint Inhibitor Targeting CD47 - [Marketwired] - Trillium Therapeutics Inc. a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has initiated dosing in its Phase 1 clinical trial ...
01/30/16 12:49 PMTrillium Therapeutics (TRIL) Acquires Privately-Held Fluorinov Pharma - FACIT has announced that Trillium Therapeutics Inc. (NASDAQ: TRIL) has acquired all of the outstanding shares of privately-held Fluorinov Pharma Inc. ("Fluorinov" or the "Company"), a FACIT portfolio company. The transaction combines Fluorinov's pipeline ...
01/28/16 07:00 AMTrillium Therapeutics Acquires Fluorinov Pharma - [CNW Group] - Trillium Therapeutics Acquires Fluorinov Pharma
01/27/16 12:34 PMTrillium Therapeutics (TRIL) Acquires Oncology Company Fluorinov Pharma - Trillium Therapeutics Inc. (Nasdaq: TRIL) announced that it has acquired all of the outstanding shares of Fluorinov Pharma Inc., a privately-held oncology company. Fluorinov has developed a proprietary medicinal chemistry platform using unique fluorine ...
01/27/16 07:16 AM8:16 am Trillium Therapeutics acquires Fluorinov Pharma for ~$7 mln, plus up to ~$25 mln of additional future payments that are contingent on Trillium achieving certain clinical and regulatory milestones -
01/27/16 07:13 AMTrillium Acquires Privately-Held Fluorinov Pharma Inc. - [Marketwired] - Trillium Therapeutics Inc. a clinical immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has acquired all of the outstanding shares of Fluorinov ...
12/08/15 12:08 PMTRILLIUM THERAPEUTICS INC. Financials -
12/03/15 06:00 AMTrillium to Provide Update on CD47 Immune Checkpoint Inhibitor Program at the 2015 American Society of Hematology Annual Meeting - [Marketwired] - Trillium Therapeutics Inc. an immuno-oncology company developing innovative therapies for the treatment of cancer, today announced it will be providing an update on its SIRPaFc immune checkpoint inhibitor ...
11/28/15 10:30 AMIs Cumberland Pharmaceuticals, Inc. (CPIX) A Good Stock To Buy? -
11/25/15 11:41 AMShould You Buy General Finance Corporation (GFN)? -
10/13/15 11:02 PMThree Canadian Biotechs with Pending Catalysts - [Accesswire] - CORAL GABLES, FL / ACCESSWIRE / October 14, 2015 / In the rush of sector-wide biotech news, especially since Hillary Clinton's now infamous tweet that rocked the entire sector late last month, some developments ...
09/30/15 06:00 AMTrillium Therapeutics Provides Update on CD47 Program - [Marketwired] - Trillium Therapeutics Inc. , an immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has completed the manufacture of clinical-grade drug product, ...
05/15/15 03:40 PMOne of the quietest days of the year on Wall Street... -
05/05/15 10:48 AMBreaking Down Steve Cohen’s Four Latest Moves in Sarepta Therapeutics (SRPT), Smith & Wesson (SWHC), More -
04/24/15 12:51 PMRidgeback Capital’s Latest Healthcare Picks: Cara Therapeutics, Trillium Therapeutics and More -
04/23/15 11:08 PMSteven Cohen Buys Trillium Therapeutics and Boosts Stake in Smith & Wesson Corp -
04/02/15 03:02 PMAegerion Pharmaceuticals, Inc. (AEGR), Joint Corp (JYNT), Trillium Therapeutics Inc. (TRIL): Latest Fund Moves in the Hot Healthcare Sector -
04/01/15 10:20 AMBiotechs Raising New Capital in Droves -
01/28/15 12:55 PMSo Far in 2015, This Choppy Market Is for Stock-Picker's Only -
About Trillium Therapeutics

Trillium Therapeutics logo

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: TRIL
  • CUSIP:
Key Metrics:
  • Previous Close: $9.33
  • 50 Day Moving Average: $10.32
  • 200 Day Moving Average: $9.85
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $72.90M
  • Current Quarter EPS Consensus Estimate: $-4.02 EPS
Additional Links:
Trillium Therapeutics (NASDAQ:TRIL) Chart for Sunday, June, 26, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha